1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Chronic Inflammation - Pipeline Review, H1 2014

Chronic Inflammation - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 61 pages

Chronic Inflammation - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Chronic Inflammation - Pipeline Review, H1 2014’, provides an overview of the Chronic Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Inflammation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Inflammation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Inflammation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Chronic Inflammation - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Inflammation Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Inflammation - Overview 8
Pipeline Products for Chronic Inflammation - Comparative Analysis 9
Chronic Inflammation - Therapeutics under Development by Companies 10
Chronic Inflammation - Therapeutics under Investigation by Universities/Institutes 12
Chronic Inflammation - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Chronic Inflammation - Products under Development by Companies 15
Chronic Inflammation - Products under Investigation by Universities/Institutes 16
Chronic Inflammation - Companies Involved in Therapeutics Development 17
Actelion Ltd 17
Incyte Corporation 18
Italfarmaco S.p.A. 19
Phenex Pharmaceuticals AG 20
Ventria Bioscience 21
Anacor Pharmaceuticals, Inc. 22
Dynamis Therapeutics, Inc. 23
Dompe Farmaceutici S.p.A. 24
InnaVirVax SA 25
Istituto Italiano di Tecnologia 26
Chronic Inflammation - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Drug for Chronic Inflammatory Condition - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
ACT-389949 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
DF-2156A - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Retinoid-Acid Receptor Related Orphan Receptor Gamma T Program - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Selective Inhibitor of Pro Inflammatory Cytokine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
AN-3485 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Monoclonal Antibody to Antagonize Alpha Epsilon Beta 7 Integrin for Chronic Inflammation - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
DYN-15 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Monocalnal Antibody for Chronic Inflammation - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
TAT-SNAP-23 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
NS-4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Anti-S100A9 Monoclonal Antibody - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
MCP-1 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Synthetic Peptides to Inhibit TACE for Chronic Inflammation - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Inactive Plasmin - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
VAC-03 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
N-Acylethanolamine Acid Amidase Inhibitors for Chronic Inflammation and Atopic Dermatitis - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Antibody to Inhibit M-DC8 Positive Monocyte for Chronic Inflammatory Diseases - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
VEN-150 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Chronic Inflammation - Dormant Projects 57
Chronic Inflammation - Product Development Milestones 58
Featured News and Press Releases 58
Apr 03, 2014: Glenmark's Novel Molecule 'GRC 27864' for Chronic Inflammatory Diseases Including Pain Entering Human Trials 58
Feb 20, 2014: La Jolla Pharmaceutical Company Receives Notice of Allowance for Patent Claims Covering Modified Pectin for Treatment of Chronic Inflammation 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables

Number of Products under Development for Chronic Inflammation, H1 2014 8
Number of Products under Development for Chronic Inflammation - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Chronic Inflammation - Pipeline by Actelion Ltd, H1 2014 17
Chronic Inflammation - Pipeline by Incyte Corporation, H1 2014 18
Chronic Inflammation - Pipeline by Italfarmaco S.p.A., H1 2014 19
Chronic Inflammation - Pipeline by Phenex Pharmaceuticals AG, H1 2014 20
Chronic Inflammation - Pipeline by Ventria Bioscience, H1 2014 21
Chronic Inflammation - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014 22
Chronic Inflammation - Pipeline by Dynamis Therapeutics, Inc., H1 2014 23
Chronic Inflammation - Pipeline by Dompe Farmaceutici S.p.A., H1 2014 24
Chronic Inflammation - Pipeline by InnaVirVax SA, H1 2014 25
Chronic Inflammation - Pipeline by Istituto Italiano di Tecnologia, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Chronic Inflammation - Dormant Projects, H1 2014 57

List of Figures

Number of Products under Development for Chronic Inflammation, H1 2014 8
Number of Products under Development for Chronic Inflammation - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.